VITR Stock Overview
Provides assisted reproduction products. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for VITR from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Vitrolife AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 212.00 |
| 52 Week High | SEK 268.00 |
| 52 Week Low | SEK 156.00 |
| Beta | 1.8 |
| 1 Month Change | -3.81% |
| 3 Month Change | -10.85% |
| 1 Year Change | 13.07% |
| 3 Year Change | -59.27% |
| 5 Year Change | 6.53% |
| Change since IPO | 2,885.92% |
Recent News & Updates
Recent updates
Is Vitrolife (STO:VITR) A Risky Investment?
Nov 27
Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Aug 21Vitrolife AB (publ) Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next
Jul 20Vitrolife AB (publ) (STO:VITR) Shares Fly 32% But Investors Aren't Buying For Growth
Jul 18Vitrolife (STO:VITR) Is Carrying A Fair Bit Of Debt
Apr 03A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Mar 07Vitrolife AB (publ) Just Missed Earnings; Here's What Analysts Are Forecasting Now
Feb 05Vitrolife AB (publ)'s (STO:VITR) Share Price Matching Investor Opinion
Jan 05Here's Why We Think Vitrolife (STO:VITR) Is Well Worth Watching
Dec 15Calculating The Intrinsic Value Of Vitrolife AB (publ) (STO:VITR)
Nov 27Is Vitrolife (STO:VITR) A Risky Investment?
Nov 06An Intrinsic Calculation For Vitrolife AB (publ) (STO:VITR) Suggests It's 27% Undervalued
Aug 25Vitrolife (STO:VITR) Could Easily Take On More Debt
Aug 03Are Vitrolife AB (publ) (STO:VITR) Investors Paying Above The Intrinsic Value?
May 26Is Vitrolife (STO:VITR) A Risky Investment?
Jan 23Vitrolife (STO:VITR) Seems To Use Debt Quite Sensibly
Oct 18Calculating The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Sep 09Is Vitrolife (STO:VITR) A Risky Investment?
Jul 07A Look At The Fair Value Of Vitrolife AB (publ) (STO:VITR)
May 26Vitrolife (STO:VITR) Seems To Use Debt Rather Sparingly
Mar 31Estimating The Fair Value Of Vitrolife AB (publ) (STO:VITR)
Feb 07Shareholder Returns
| VITR | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.0% | -0.3% | -2.2% |
| 1Y | 13.1% | 6.2% | 6.1% |
Return vs Industry: VITR exceeded the Swedish Biotechs industry which returned 7.5% over the past year.
Return vs Market: VITR exceeded the Swedish Market which returned 7.3% over the past year.
Price Volatility
| VITR volatility | |
|---|---|
| VITR Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: VITR has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: VITR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 1,111 | Bronwyn Brophy O´Connor | www.vitrolife.com |
Vitrolife AB (publ) provides assisted reproduction products. It also offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. In addition, the company offers EmbryoScope and time-lapse systems; time-lapse dishes; and evaluation tools for time-lapse systems.
Vitrolife AB (publ) Fundamentals Summary
| VITR fundamental statistics | |
|---|---|
| Market cap | SEK 28.70b |
| Earnings (TTM) | -SEK 3.80b |
| Revenue (TTM) | SEK 3.56b |
8.1x
P/S Ratio-7.5x
P/E RatioIs VITR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VITR income statement (TTM) | |
|---|---|
| Revenue | SEK 3.56b |
| Cost of Revenue | SEK 1.49b |
| Gross Profit | SEK 2.07b |
| Other Expenses | SEK 5.87b |
| Earnings | -SEK 3.80b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | -28.10 |
| Gross Margin | 58.17% |
| Net Profit Margin | -107.03% |
| Debt/Equity Ratio | 14.6% |
How did VITR perform over the long term?
See historical performance and comparisonDividends
0.5%
Current Dividend Yield-4%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 03:55 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vitrolife AB (publ) is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Cassel | ABG Sundal Collier Sponsored |
| null null | ABG Sundal Collier Sponsored |
| Kallum Titchmarsh | BofA Global Research |